An Overview of the Investigational HIV-1 Maturation Inhibitor GSK3739937 (VH3739937)

I. Introduction to GSK3739937

A. Overview of GSK3739937 (VH3739937)

GSK3739937, also identified in scientific literature and development programs as VH3739937 or by the internal research code VH-937, is an investigational small molecule compound.[1] It has been developed primarily for its potential therapeutic application in the management of Human Immunodeficiency Virus Type 1 (HIV-1) infection.[1] The compound is structurally related to GSK3640254, an earlier-generation HIV-1 maturation inhibitor.[5] The consistent use of dual nomenclature, GSK3739937 and VH3739937, across research publications and trial registries is noteworthy, with "VH" likely indicating the involvement of ViiV Healthcare in its development. This is a common practice in pharmaceutical development where internal research codes (e.g., VH-937) and corporate identifiers (e.g., GSK3739937) may be used concurrently. Clarification of this nomenclature is important for accurately tracking the compound's progress through various stages of research and development.

B. Chemical Nature and Drug Class (HIV-1 Maturation Inhibitor)

GSK3739937 is classified as an HIV-1 maturation inhibitor (MI), a novel class of antiretroviral agents that target the late stages of the HIV-1 replication cycle.[2] It is a small molecule drug with the molecular formula C49H70N4O5S and CAS Registry number 2122781-86-4.[2] GSK3739937 represents an advanced generation MI, distinguished by specific chemical modifications designed to improve upon earlier compounds in its class. Notably, it features a 4-cyanopyridyl ether moiety which replaces a fluorine atom present in the predecessor compound, GSK3640254 (GSK254). Additionally, the introduction of aromatic methylene ethers alpha (α) to the carboxylic acid moiety was a deliberate structural change.[2] These chemical alterations were not arbitrary but were the result of targeted medicinal chemistry efforts. The goal was to enhance the antiviral profile, particularly to confer activity against viral strains harboring mutations like A364V, which is a known resistance pathway for earlier MIs, and to optimize pharmacokinetic properties suitable for less frequent dosing.[2] This strategic design aimed to achieve a superior overall antiviral efficacy combined with a pharmacokinetic profile amenable to infrequent administration, a desirable attribute for long-term HIV therapy.[3]

C. Originator/Developer (ViiV Healthcare)

GSK3739937 was originated and is under development by ViiV Healthcare Ltd. and ViiV Healthcare UK Ltd..[2] ViiV Healthcare is a pharmaceutical company specializing exclusively in the research and development of medicines for HIV.[9] The development of GSK3739937 is thus situated within a corporate environment possessing deep institutional knowledge and extensive experience in HIV virology, antiretroviral therapy, and the multifaceted challenges of drug development in this field. ViiV Healthcare's pipeline emphasizes the development of long-acting antiretroviral options, a strategic focus that aligns with the pharmacokinetic characteristics observed for GSK3739937, particularly its long half-life and potential for infrequent dosing regimens.[10]

II. Mechanism of Action

A. Targeting HIV-1 Maturation

Maturation inhibitors (MIs) represent an investigational class of antiretroviral drugs that exert their effect by targeting the final stages of the HIV-1 life cycle.[7] During this critical maturation phase, profound structural rearrangements occur within newly formed HIV-1 virions. These changes are orchestrated by the HIV-1 protease, which cleaves the viral structural polyprotein Gag at multiple sites. This precise proteolytic processing is essential for the transformation of immature, non-infectious viral particles into mature, infectious virions, characterized by the formation of a condensed conical ribonucleoprotein core.[6] Any interference or alteration in the efficiency of these maturation steps can significantly impair viral infectivity, rendering the progeny virions incapable of establishing new infections.[6]

B. Specific Molecular Interactions and Inhibition of Protease Cleavage

GSK3739937 exerts its antiviral effect by specifically interfering with a critical, final step in the HIV-1 maturation cascade. It selectively blocks the proteolytic cleavage event between the capsid protein (CA, also known as p24) and spacer peptide 1 (SP1) within the Gag polyprotein precursor.[5] This targeted inhibition is a distinguishing feature of this class of MIs. The consequence of this blockade is the failure to remove SP1 from the C-terminal end of CA, which is an indispensable step for the proper assembly and condensation of the viral core.[5] As a result, the virions produced in the presence of GSK3739937 are structurally aberrant and non-infectious. The mechanism of CA-SP1 cleavage inhibition was substantiated in biochemical assays utilizing virus-like particles (VLPs). These experiments demonstrated that GSK3739937 effectively prevented the appearance of mature p24 (CA) from Gag precursors when VLPs were incubated with HIV-1 protease and the inhibitor.[6]

The precision of GSK3739937 for the CA-SP1 cleavage site is a key aspect of its mechanism. This specificity differentiates MIs from HIV protease inhibitors (PIs). PIs act by directly inhibiting the enzymatic activity of the HIV protease, thereby affecting all Gag and Gag-Pol polyprotein cleavage events. In contrast, MIs like GSK3739937 are understood to bind to the Gag substrate itself, specifically to CA-SP1 hexamers, making the CA-SP1 junction inaccessible or resistant to cleavage by the protease, even if the protease itself remains active.[6] This substrate-targeted inhibition represents a more nuanced approach to disrupting viral maturation and may contribute to a distinct resistance profile compared to PIs. The ultimate consequence of this incomplete maturation is the production of virions with improperly formed cores, which, although they may be assembled and released from the host cell, are incapable of successfully infecting new target cells, thus halting the viral replication cycle at a crucial late stage.[5]

III. Preclinical Evaluation

A. In Vitro Antiviral Activity

1. Potency against Laboratory Strains and Clinical Isolates

Preclinical in vitro studies demonstrated that VH3739937 (GSK3739937) possesses potent antiviral activity against a broad range of HIV-1 variants. The compound exhibited high potency against a panel of eight HIV-1 laboratory strains, with half-maximal effective concentration (EC50​) values consistently in the low nanomolar range, typically between 1 and 5 nM (specifically 1.3 to 4.4 nM reported in one study).[5] This activity was observed against both CXCR4-tropic and CCR5-tropic viruses, indicating broad efficacy irrespective of co-receptor usage.[5]

Furthermore, VH-937 was evaluated against a diverse panel of 42 HIV-1 clinical isolates, encompassing six major subtypes (A, CRF01_AE, B, C, D, and F). All clinical isolates tested were susceptible to the inhibitor, with EC50​ values remaining at or below 5 nM.[5] Importantly, no discernible differences in susceptibility were noted among the various HIV-1 subtypes examined.[5] Activity was also reported against HIV-1 isolates from the less common Group N and Group O, with EC50​ values of 3.1 nM and 4.7 nM, respectively.[6] Additionally, antiviral activity was observed against one of two HIV-2 laboratory strains tested.[5] The maximal percent inhibition (MPI) achieved by VH-937 was generally high, typically at or above 92%, indicating a profound suppression of viral replication at effective concentrations.[6] This consistent low nanomolar potency across a wide array of HIV-1 strains, including laboratory-adapted strains, diverse clinical isolates, and multiple subtypes, establishes a strong foundation for its potential as an antiretroviral agent.

2. Activity against Maturation Inhibitor-Resistant Polymorphisms

A critical aspect of VH-937's preclinical assessment was its activity against HIV-1 variants harboring Gag protein polymorphisms known to reduce the susceptibility to earlier-generation maturation inhibitors.[5] The A364V substitution in Gag is a particularly notable polymorphism associated with resistance to MIs.[2] In multi-cycle antiviral assays, which assess viral replication over several rounds, VH-937 demonstrated retained activity against a virus engineered to carry the A364V polymorphism, with an EC50​ of 5 nM and an MPI of 95%.[5] Other viruses with polymorphisms that conferred reduced susceptibility to previous MIs were also inhibited by VH-937 at EC50​ values ≤ 8.0 nM, with MPI values remaining ≥ 92% in these multi-cycle assays.[6]

Interestingly, a discrepancy was observed when evaluating the A364V mutant in single-cycle versus multi-cycle assays. In single-cycle assays, which measure only one round of infection, VH-937 was less potent against the A364V variant, yielding an EC50​ of 32.0 nM and a reduced MPI of 57%.[6] This difference suggests that while the A364V mutation does directly impact the interaction of VH-937 with its target or the processing of the Gag precursor, the overall effect on viral replication over multiple cycles might be less pronounced. This could be attributed to potential fitness costs imposed by the A364V mutation that become more apparent in multi-cycle replication, or to differences in drug exposure dynamics and the accumulation of inhibitory effects over successive replication rounds in the multi-cycle format.

B. Resistance Profile

1. Resistance Selection Studies and Emergent Mutations

In vitro resistance selection studies were conducted by culturing HIV-1 in the presence of escalating concentrations of VH-937. These experiments identified the A364V substitution as an emergent mutation in one of four independent cultures.[5] This finding is consistent with A364V being a common resistance pathway selected by MIs.[2] Other substitutions were also selected by VH-937 pressure in these studies, including L363W, a double mutant D93N/T332P, and a triple mutant H144Y/V362I/R384K.[6]

2. Impact of Key Mutations on Susceptibility and Viral Fitness

The functional consequences of these selected mutations were further investigated. While A364V conferred a degree of reduced susceptibility, particularly in single-cycle assays, VH-937 retained partial activity against this mutant, suggesting that the mutation does not completely abrogate drug binding or efficacy.6

A significant observation was that several of the other selected mutations or combinations thereof, such as L363W, T332P-containing viruses, D93N/T332P, and H144Y/V362I/R384K, resulted in viruses that were either non-functional or exhibited severely impaired replication capacity in multi-cycle assays, even if they showed high-level resistance in single-cycle assays.6 For instance, T332P and L363W are not common natural polymorphisms, and their induction of high-level resistance in vitro at the cost of viral replicative capacity suggests a substantial fitness burden.6 This high fitness cost associated with certain resistance pathways could limit their clinical emergence and persistence, potentially offering a clinical advantage for VH-937.

3. Dissociation Kinetics and Correlation with Resistance

To understand the biophysical basis of resistance, the dissociation kinetics of VH-937 from VLPs were measured. The estimated dissociative half-life (t1/2​) of VH-937 from wild-type Gag VLPs was remarkably long, approximately 3 days (4125 minutes).[5] This slow off-rate indicates a stable and prolonged interaction with its target. In stark contrast, the dissociative t1/2​ of VH-937 from VLPs containing the A364V mutation was dramatically shorter, measured at only 29 minutes.[5] This significantly more rapid dissociation from the A364V-mutated target provides a compelling molecular explanation for the reduced susceptibility conferred by this mutation.[6] A faster off-rate implies that the drug does not remain bound to its target for a sufficient duration to effectively inhibit the CA-SP1 cleavage, particularly if the enzymatic processing by HIV-1 protease is relatively efficient.

C. Cytotoxicity and Selectivity Index

The cytotoxic potential of VH-937 was assessed in various cell lines. The mean 50% cytotoxic concentration (CC50​) in MT-2 cells was determined to be 11.4 µM.[6] In a broader panel of cell lines, CC50​ values ranged from 0.36 µM to 11.4 µM.[6] When these micromolar cytotoxicity values are compared to the low nanomolar EC50​ values required for antiviral activity (e.g., ≤5 nM or 0.005 µM), a favorable selectivity index is indicated. This wide therapeutic window observed in vitro suggests that VH-937 can achieve effective viral inhibition at concentrations significantly below those that induce host cell toxicity, a fundamental prerequisite for a viable therapeutic agent.

D. Protein Binding and Target Clinical Concentrations

In the presence of 100% human serum, VH-937 was found to be approximately 93.3% protein bound.5 Similar results, indicating an implied protein-bound fraction of 93.1%, were observed under high-serum conditions in other assays.6 High protein binding is a common characteristic of many drugs and means that a substantial portion of the drug in circulation is bound to plasma proteins, with only the unbound (free) fraction being pharmacologically active. This underscores the necessity for VH-937 to possess high intrinsic potency (low nanomolar EC50​ values).

Based on these protein binding characteristics and the in vitro inhibitory activities against a range of HIV-1 variants, including those with Gag polymorphisms, a target trough plasma concentration (Cmin​) of 312 nM was established for clinical development.5 This target Cmin​ for total drug is designed to ensure that the free drug concentrations achieved in vivo are sufficient to provide robust antiviral coverage against the vast majority of circulating HIV-1 strains, including those with potentially reduced susceptibility.

Table 1: Summary of In Vitro Antiviral Potency and Cytotoxicity of GSK3739937 (VH-937)

Virus Type/Strain	EC50​ (nM)	MPI (%)	CC50​ (µM, MT-2 cells)	Selectivity Index (approx., vs. WT HIV-1)	Source(s)
HIV-1 Laboratory Strains (average of 8)	1.3 - 4.4	≥92	11.4	~2600 - 8700	5
HIV-1 Clinical Isolates (average of 42, 6 subtypes)	≤5.0	≥92	11.4	≥2280	5
HIV-1 A364V (multi-cycle assay)	5.0	95	11.4	~2280	5
HIV-1 A364V (single-cycle assay)	32.0	57	11.4	~356	6
HIV-1 Wild-Type (NL4-3, multi-cycle for reference)	~2.0	≥95	11.4	~5700	6

Note: MPI = Maximal Percent Inhibition. Selectivity Index calculated as CC50​ / EC50​ using representative EC50​ values.

IV. Clinical Development Program

A. Phase 1 Clinical Trial (NCT04493684)

1. Study Design, Objectives, and Participant Population

The initial human clinical evaluation of GSK3739937 was conducted under trial NCT04493684. This was a Phase 1, first-in-human, double-blind, randomized, placebo-controlled study designed to assess the safety, tolerability, and pharmacokinetics (PK) of GSK3739937 in healthy adult participants.[2] The study incorporated both single ascending dose (SAD) and multiple ascending dose (MAD) cohorts. An additional open-label component (Part 3) was included to evaluate relative bioavailability and the effect of food on absorption.[11] The primary objective was the assessment of safety and tolerability, with PK characterization as a secondary objective.[2] The trial commenced in July 2020 and concluded in August 2021, conducted at a single site in the United States.[12] A total of 91 healthy participants were enrolled.[2] The SAD part explored single oral doses ranging from 10 mg to 800 mg. The MAD part involved up to 18 once-daily doses of 25 mg to 100 mg, or 3 once-weekly doses of 500 mg.[11] The study was conducted under Investigational New Drug (IND) application number 147773 and European Union Drug Regulating Authorities Clinical Trials Database (EudraCT) number 2020-002834-34.[13]

2. Pharmacokinetic Profile

The PK profile of GSK3739937 in healthy volunteers revealed several key characteristics. A notably long terminal phase half-life of approximately 3 days was consistently observed across all dose levels following both single and repeated administrations.2 This extended half-life is a significant finding, as it provides a strong rationale for the potential of infrequent oral dosing, such as a weekly regimen.2

In the single-dose escalation part of the study, the geometric mean maximum plasma concentration (Cmax​) and total drug exposure (Area Under the Curve, AUC) demonstrated dose-proportional increases, indicating predictable PK behavior with increasing doses.2 Following multiple dosing, drug accumulation was observed, as expected for a compound with a long half-life. The accumulation in exposure was approximately 6- to 7-fold with once-daily dosing and around 1.7-fold after once-weekly treatment.2

The study also investigated the impact of food and formulation on the bioavailability of GSK3739937. Administration with food significantly enhanced absorption. The bioavailability of GSK3739937 was more than 2-fold higher when the tablet formulation was administered in a fed state compared to a fasted state.[2] Furthermore, when administered with food, the tablet formulation resulted in 1.35- to 1.40-fold greater bioavailability compared to a powder-in-bottle (PiB) oral suspension.[2] One summary reported that the amount of drug and the time it remained in the body was approximately 40% higher when given as a tablet with food compared to an oral suspension with food.[12] This positive food effect is a clinically relevant PK characteristic, necessitating clear administration guidelines to ensure consistent drug exposure.

3. Safety and Tolerability

In this Phase 1 study involving 91 healthy participants, GSK3739937 was found to be generally safe and well-tolerated across the dose ranges evaluated.[2] No unexpected or dose-limiting safety events were reported.[2] All adverse events (AEs) experienced by participants receiving GSK3739937 were classified as Grade 1 or Grade 2 in severity, and all AEs resolved during the course of the study.[2] Out of the 91 enrolled participants, 38 reported a total of 81 AEs.[2] The most frequently reported drug-related AEs were gastrointestinal in nature, accounting for 14 out of 17 such events (82%).[2] The favorable safety and PK profile observed in this initial human study, particularly the long half-life and good tolerability, supported the continued investigation of GSK3739937, especially with an infrequent dosing schedule in mind.

B. Phase 2 Clinical Trial (NCT06061081)

1. Study Design and Objectives

Following the Phase 1 investigations, GSK3739937 (VH3739937) advanced to a Phase 2 clinical trial, registered as NCT06061081. This study was designed as a randomized, double-blind, placebo-controlled, adaptive trial intended to evaluate the antiviral effect, safety, tolerability, and pharmacokinetics of VH3739937 in treatment-naive adults living with HIV-1.[2] The primary purpose of this Phase 2 study was to assess the antiviral activity of VH3739937 when administered as monotherapy for a short period.[14] According to the study protocol, participants were scheduled to initiate standard combination antiretroviral therapy (cART) on Study Day 8.[14] The trial aimed to enroll 21 participants aged between 18 and 65 years.[14]

2. Trial Status (Terminated) and Available Information

The clinical trial NCT06061081 is listed with a status of "Terminated".[2] According to standard clinical trial terminology, a "Terminated" status indicates that the study was stopped prematurely and will not resume.[15] The specific reasons for the termination of this Phase 2 trial are not explicitly detailed in the provided documentation. This cessation of an efficacy-seeking study represents a significant event in the drug's development trajectory, often signaling challenges related to efficacy, safety in the target patient population, strategic shifts, or other unforeseen issues that were not apparent from the Phase 1 studies in healthy volunteers.

C. Other Clinical Investigations (e.g., NCT06533280 - Withdrawn)

Another clinical study, NCT06533280, was planned for VH3739937. This was intended to be a multi-part Phase 1 study in healthy participants, designed to further assess safety, tolerability, and pharmacokinetics, including multiple ascending dose (MAD) and relative bioavailability (RBA) cohorts, with optional components to evaluate food effects and drug-drug interactions.[2] However, the status of NCT06533280 is listed as "Withdrawn".[2] A "Withdrawn" status signifies that the study was stopped before the first participant was enrolled.[15] The withdrawal of this additional Phase 1 study, which would typically serve to further characterize the drug's properties or explore interactions necessary for broader development, particularly when considered alongside the termination of the Phase 2 trial, suggests a significant halt or major reassessment of the GSK3739937 development program.

D. Regulatory Status

The Phase 1 clinical trial NCT04493684 was conducted under IND number 147773 in the United States and EudraCT number 2020-002834-34 in Europe.[13] The available information does not indicate that GSK3739937 has received any special regulatory designations from the U.S. Food and Drug Administration (FDA), such as Fast Track, Breakthrough Therapy, or Orphan Drug designation, nor any similar designations like PRIME (Priority Medicines) from the European Medicines Agency (EMA).[16] While these designations are often sought to expedite the development and review of promising drugs for serious conditions with unmet medical needs, their absence in the documentation for GSK3739937 (at the time of the source documents) might imply that the criteria for such designations had not been met or that applications for them were not pursued or publicized.

Table 2: Overview of GSK3739937 Clinical Trials

Trial ID	Phase	Study Title/Purpose	Key PK Findings (Brief)	Key Safety Findings (Brief)	Status	Reason for Status (if available)	Source(s)
NCT04493684	Phase 1	Safety, tolerability, PK of single and multiple doses in healthy participants; relative bioavailability and food effect.	~T1/2​ ~3 days; dose-proportional exposure (SAD); accumulation as expected; >2-fold increased bioavailability with food (tablet).	Generally well-tolerated; all AEs Grade 1/2, mostly GI; no DLTs.	Completed	N/A	2
NCT06061081	Phase 2	Antiviral effect, safety, tolerability, PK of VH3739937 monotherapy in treatment-naive adults with HIV-1.	Not available due to termination.	Not available due to termination.	Terminated	Not specified in sources.	2
NCT06533280	Phase 1	Safety, tolerability, PK in healthy participants (MAD, RBA, food effect, drug interaction cohorts).	Not applicable (study withdrawn before enrollment).	Not applicable (study withdrawn before enrollment).	Withdrawn	Not specified in sources.	2

V. Therapeutic Potential and Position in HIV Management

A. Potential Advantages

GSK3739937 exhibited several characteristics in its early development that suggested potential advantages as an HIV-1 therapeutic. Its long pharmacokinetic half-life of approximately 3 days, observed in Phase 1 studies, offered the prospect of infrequent oral dosing, potentially once weekly.[2] Such a regimen could significantly improve medication adherence, a cornerstone of successful long-term HIV management, compared to daily oral therapies.[21] Poor adherence is a major challenge that can lead to virologic failure and the development of drug resistance. A weekly oral option would align with the broader therapeutic trend towards developing long-acting antiretrovirals to ease treatment burden.[21]

Preclinically, GSK3739937 demonstrated potent antiviral activity against a wide array of HIV-1 strains. This included activity against some viral variants carrying Gag polymorphisms, such as A364V, which are known to confer resistance to earlier-generation maturation inhibitors.[2] This attribute suggested a potential role in treatment regimens for patients with pre-existing resistance to other MIs or as a component of salvage therapy.

The novel mechanism of action, specifically targeting the cleavage of CA-SP1, distinguishes MIs from all other existing classes of antiretroviral drugs.[6] This offers a new target in the HIV-1 lifecycle, which could be particularly valuable for patients who have developed resistance to multiple other antiretroviral classes or for use in novel combination strategies. Furthermore, the Phase 1 studies in healthy volunteers indicated a favorable safety and tolerability profile for GSK3739937 at the doses tested.[2]

B. Considerations from Clinical Development Setbacks

Despite the promising early-phase data, the clinical development trajectory of GSK3739937 encountered significant hurdles. The termination of the Phase 2 efficacy-seeking trial (NCT06061081) and the withdrawal of the subsequent Phase 1 trial (NCT06533280) before enrollment raise substantial questions regarding the drug's future viability or reflect a strategic shift in ViiV Healthcare's development priorities.[2] The specific reasons for these decisions are not detailed in the available public information, creating a critical information gap. This lack of transparency makes it challenging to ascertain whether the setbacks were due to insufficient efficacy in HIV-infected individuals, unexpected safety concerns in this population (who may differ from healthy volunteers in terms of immune status or concomitant medications), the emergence of rapid or problematic drug resistance in vivo, or strategic and commercial considerations by the developer. This uncertainty casts considerable doubt over the drug's path forward.

C. Comparison with Existing Antiretroviral Classes (Brief Context)

Current standard-of-care antiretroviral therapy (ART) for HIV-1 infection typically involves the daily administration of a combination of drugs from different classes, such as integrase strand transfer inhibitors (INSTIs), nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs), non-nucleoside reverse transcriptase inhibitors (NNRTIs), and protease inhibitors (PIs).[22] Maturation inhibitors like GSK3739937 represent a distinct therapeutic class by targeting a different, later stage in the viral replication cycle.[6] This mechanistic novelty provides the theoretical potential for activity against viral strains that have developed resistance to established drug classes. The development of GSK3739937, with its potential for weekly oral dosing, also aligns with the significant ongoing efforts in the HIV field to develop long-acting formulations and regimens aimed at improving patient adherence, convenience, and quality of life.[21] If the underlying reasons for its developmental setbacks could be overcome, GSK3739937's unique attributes might still allow it to fill a niche, particularly for heavily treatment-experienced patients or those with complex resistance profiles not adequately addressed by other long-acting options.

VI. Summary, Conclusions, and Recommendations

A. Recapitulation of Key Findings

GSK3739937 (VH3739937) is an investigational, orally administered HIV-1 maturation inhibitor developed by ViiV Healthcare. Its mechanism of action involves the specific inhibition of the cleavage between the capsid (CA) and spacer peptide 1 (SP1) in the Gag polyprotein, a critical late step in viral maturation. Preclinical studies demonstrated potent in vitro antiviral activity against a broad range of HIV-1 laboratory strains and clinical isolates, including activity against the A364V polymorphism known to confer resistance to earlier maturation inhibitors. Phase 1 clinical trials in healthy volunteers showed that GSK3739937 has a long pharmacokinetic half-life of approximately 3 days, supporting the potential for infrequent (e.g., weekly) oral dosing. The drug exhibited dose-proportional pharmacokinetics and was generally well-tolerated in healthy subjects, with a significant positive food effect on bioavailability. However, a Phase 2 trial (NCT06061081) designed to evaluate its antiviral efficacy in treatment-naive adults with HIV-1 was terminated prematurely. Subsequently, a planned further Phase 1 trial (NCT06533280) was withdrawn before participant enrollment.

B. Assessment of Current Developmental Status

GSK3739937 initially showed considerable promise as a next-generation HIV-1 maturation inhibitor with a pharmacokinetic profile amenable to long-acting oral administration. The preclinical potency, including against certain resistant variants, and the favorable safety and tolerability in initial human studies were encouraging. However, the unexplained termination of its key Phase 2 efficacy study and the withdrawal of a supporting Phase 1 study indicate that the clinical development program for GSK3739937 has been, at a minimum, significantly halted or substantially re-evaluated. Without publicly available information detailing the reasons for these clinical development setbacks, a definitive assessment of GSK3739937's future prospects is challenging. The current evidence suggests a stark contrast between early promise and later-stage developmental impediments.

C. Recommendations

From a medical research perspective, the following considerations are pertinent regarding the status and potential future of GSK3739937:

1. Transparency Regarding Trial Outcomes: For the scientific and medical community to fully understand the trajectory of GSK3739937 and the challenges encountered, disclosure of the specific reasons for the termination of the Phase 2 trial (NCT06061081) would be invaluable. Understanding whether the termination was due to insufficient efficacy, unexpected safety signals in the HIV-infected population, problematic resistance development, or strategic/commercial factors is crucial for informing future research in this drug class.
2. Further Preclinical Resistance Characterization: Should there be any consideration for reviving development, a more profound understanding of the resistance profile would be beneficial. This includes detailed characterization of resistance pathways beyond A364V, particularly focusing on mutations that may emerge in vivo and retain significant viral fitness despite conferring resistance.
3. Exploration in Specific Therapeutic Niches: If the reasons for trial termination were related to broad applicability or efficacy as a widely used agent, but the drug retains unique advantages (e.g., potent activity against highly specific multi-MI-resistant strains not covered by other agents), its development for a more targeted, perhaps orphan-like, indication could theoretically be considered. However, the feasibility of such an approach would heavily depend on the undisclosed reasons for the Phase 2 termination.
4. Assessment of Combination Potential: If the termination of the Phase 2 monotherapy study was due to insufficient antiviral activity as a single agent, but the safety profile in HIV-infected individuals was acceptable, exploring GSK3739937's potential as part of a long-acting oral combination regimen could be a theoretical avenue. This would require identifying suitable partner antiretrovirals and, critically, addressing the primary concerns that led to the initial program halt.

In conclusion, while GSK3739937 demonstrated promising foundational characteristics as a novel antiretroviral agent, its clinical development path has been significantly interrupted. The lack of detailed information regarding the reasons for the cessation of later-stage clinical trials currently obscures its future therapeutic potential. Further clarity on these issues is essential for any informed reassessment of its role in HIV management.

Works cited

1. VH 3739937 Inhibitor Overview - Ontosight.ai, accessed June 11, 2025, https://ontosight.ai/glossary/term/vh-3739937-inhibitor-overview--67a0ddc56c3593987a505c32
2. Global Drug Intelligence Database - Synapse, accessed June 11, 2025, https://synapse.patsnap.com/drug/11523abe9f724aa8b47811dc352bb700
3. Fipravirimat - Drug Targets, Indications, Patents - Patsnap Synapse, accessed June 11, 2025, https://synapse.patsnap.com/drug/857082ac7d33433cbc76f53dc04fcc78
4. Preclinical Profile of the HIV-1 Maturation Inhibitor VH3739937 - PMC - PubMed Central, accessed June 11, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC11512352/
5. CROI 2024_McAuliffe_MI'937 Preclin Virology - GSK, accessed June 11, 2025, https://medinfo.gsk.com/5f95dbd7-245e-4e65-9f36-1a99e28e5bba/752e4044-a6f9-4554-853a-afcb90ecd7d7/752e4044-a6f9-4554-853a-afcb90ecd7d7_viewable_rendition__v.pdf
6. (PDF) Preclinical Profile of the HIV-1 Maturation Inhibitor VH3739937, accessed June 11, 2025, https://www.researchgate.net/publication/384321730_Preclinical_Profile_of_the_HIV-1_Maturation_Inhibitor_VH3739937
7. Efficacy and Safety of the HIV-1 Maturation Inhibitor GSK3640254 + 2 NRTIs in Treatment - ViiV Exchange, accessed June 11, 2025, https://viivexchange.com/content/dam/cf-viiv/viivexchange/medical/pdf/eacs-2023-joshi-domino-slides-disclaimer.pdf
8. Preclinical Profile of the HIV-1 Maturation Inhibitor VH3739937 - MDPI, accessed June 11, 2025, https://www.mdpi.com/1999-4915/16/10/1508
9. HIV medicines in development - ViiV Healthcare, accessed June 11, 2025, https://viivhealthcare.com/hiv-research-and-innovation/medicines-development/
10. Bibliography for ViiV Healthcare Product Pipeline Summary, accessed June 11, 2025, https://assets.gskstatic.com/viiv/viivhcmedinfo/pipeline-application/assets/maturation.pdf
11. A phase I, first-in-human study investigating the safety, tolerability, and pharmacokinetics of the maturation inhibitor GSK3739937 - PubMed, accessed June 11, 2025, https://pubmed.ncbi.nlm.nih.gov/37269076/
12. Study names Who sponsored this study? General information about the clinical study - Amazon S3, accessed June 11, 2025, https://s3.amazonaws.com/trs-cor-9011/5011423/f4ea9909-b820-408f-9853-2680def13fe7/d350d145-dbbd-4acf-a11a-36d9d2c0fa8f/viiv-212548-plain-language-summary_English-v1.pdf
13. 212548 Official Title of Study: A Double-Blind (Sponsor Unblinded), Randomized, Placebo- Controll - ClinicalTrials.gov, accessed June 11, 2025, https://cdn.clinicaltrials.gov/large-docs/84/NCT04493684/Prot_000.pdf
14. A Study to Investigate the Antiviral Effect, Safety, Tolerability and Pharmacokinetics of VH3739937 in in Treatment-Naive Adults Living With HIV-1 - ClinicalTrials.Veeva, accessed June 11, 2025, https://ctv.veeva.com/study/a-study-to-investigate-the-antiviral-effect-safety-tolerability-and-pharmacokinetics-of-vh3739937
15. ClinicalTrials.gov: Home, accessed June 11, 2025, https://clinicaltrials.gov/
16. Fostemsavir: First Approval - ResearchGate, accessed June 11, 2025, https://www.researchgate.net/publication/343919617_Fostemsavir_First_Approval
17. Oral Histone Deacetylase Inhibitor Receives FDA Fast Track Designation for PV, accessed June 11, 2025, https://www.docwirenews.com/post/oral-histone-deacetylase-inhibitor-receives-fast-track-designation-for-pv
18. Following Positive Phase 2 Results and Orphan Drug Designation, Biodexa's FAP Drug Receives FDA Fast Track Status - BioSpace, accessed June 11, 2025, https://www.biospace.com/press-releases/following-positive-phase-2-results-and-orphan-drug-designation-biodexas-fap-drug-receives-fda-fast-track-status
19. PRIME: priority medicines | European Medicines Agency (EMA) - European Union, accessed June 11, 2025, https://www.ema.europa.eu/en/human-regulatory-overview/research-development/prime-priority-medicines
20. What is the PRIME Designation in EMA? - DDReg, accessed June 11, 2025, https://www.ddregpharma.com/what-is-the-prime-designation
21. Advances in HIV Treatment: Long-Acting Antiretrovirals and the Path Toward a Cure - MDPI, accessed June 11, 2025, https://www.mdpi.com/2227-9059/13/2/493
22. HIV Treatment: The Basics | NIH - HIVinfo, accessed June 11, 2025, https://hivinfo.nih.gov/understanding-hiv/fact-sheets/hiv-treatment-basics
23. New long-acting HIV drugs show promising early results - Aidsmap, accessed June 11, 2025, https://www.aidsmap.com/news/mar-2025/new-long-acting-hiv-drugs-show-promising-early-results